Enhanced stability of levodopa and benserazide fixed-dose combination tablets through optimized production processes
Authors:
- Onur PinarbasliOPOnur Pinarbasli
- N. Egesen KokNKN. Egesen Kok
- Feristah BilginFBFeristah Bilgin
- Nagehan SarracogluNSNagehan Sarracoglu
Open Access
- 26 May 2025
- journal article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 211
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Development, Validation, and Quantification of Organic Impurities with Mass Balance in the Levodopa and Benserazide Hydrochloride Pharmaceutical Dosage FormJournal of Analytical Chemistry, 2024
- Pharmacological Treatment of Parkinson DiseaseJAMA, 2014
- Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®BMC Pharmacology and Toxicology, 2013
- Therapies in Parkinsonʼs diseaseCurrent Opinion in Neurology, 2012
- Neurobiology and treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 2009
- The history of dopamine and levodopa in the treatment of Parkinson's diseaseMovement Disorders, 2008
- Levodopa and the Progression of Parkinson's DiseaseNew England Journal of Medicine, 2004
- The Frequency of Idiopathic Parkinson's Disease by Age, Ethnic Group, and Sex in Northern Manhattan, 1988–1993American Journal of Epidemiology, 1995
- Reversal of Experimental Parkinsonism by Lesions of the Subthalamic NucleusScience, 1990
- "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPYThe Lancet, 1976